Display Settings:

Format

Send to:

Choose Destination
    Vaccine. 2010 Mar 19;28(14):2624-35. Epub 2010 Jan 26.

    Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?

    Source

    University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, 3508 GA Utrecht, The Netherlands. m.j.j.mangen@uncutrecht.nl

    Abstract

    This study assessed whether the inclusion of two rotavirus (RV) vaccines in the Dutch national immunization programme is cost-effective. Costs and outcomes in unvaccinated and vaccinated populations are compared for a time period of 20 years. In the baseline, assuming competitive market forces in relation to vaccine costs, Rotarix is more cost-effective than RotaTeq, resulting in a cost-utility ratio (CUR) of euro 53,000 per DALY (third payer perspective) and euro 49,000 per DALY (societal perspective), but both considered as being not cost-effective. Vaccine-related costs, annual epidemic-size, and indirect protection are the major factors that determine cost-effectiveness of RV vaccination.

    Copyright 2010 Elsevier Ltd. All rights reserved.

    PMID:
    20109593
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk